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Limited structural information of drug targets, cellular toxicity possessed by lead compounds, and large amounts of potential
leads are the major issues facing the design-oriented approach of discovering new leads. In an attempt to tackle these issues,
we have developed a process of virtual screening based on the observation that conformational rearrangements of the dengue
virus envelope protein are essential for the mediation of viral entry into host cells via membrane fusion. Screening was based
solely on the structural information of the Dengue virus envelope protein and was focused on a target site that is presumably
important for the conformational rearrangements necessary for viral entry. To circumvent the issue of lead compound toxicity,
we performed screening based on molecular docking using structural databases of medical compounds. To enhance the
identification of hits, we further categorized and selected candidates according to their novel structural characteristics. Finally,
the selected candidates were subjected to a biological validation assay to assess inhibition of Dengue virus propagation in
mammalian host cells using a plaque formation assay. Among the 10 compounds examined, rolitetracycline and doxycycline
significantly inhibited plaque formation, demonstrating their inhibitory effect on dengue virus propagation. Both compounds
were tetracycline derivatives with IC50s estimated to be 67.1 mM and 55.6 mM, respectively. Their docked conformations
displayed common hydrophobic interactions with critical residues that affected membrane fusion during viral entry. These
interactions will therefore position the tetracyclic ring moieties of both inhibitors to bind firmly to the target and,
subsequently, disrupt conformational rearrangement and block viral entry. This process can be applied to other drug targets in
which conformational rearrangement is critical to function.
Citation: Yang J-M, Chen Y-F, Tu Y-Y, Yen K-R, Yang Y-L (2007) Combinatorial Computational Approaches to Identify Tetracycline Derivatives as
Flavivirus Inhibitors. PLoS ONE 2(5): e428. doi:10.1371/journal.pone.0000428
INTRODUCTION
The Dengue virus (DV) belongs to the Flavivirus family and has
become a major threat to public health globally, especially in
tropical and subtropical areas, due to the increases in population
density and environmental changes. There are approximately 2.5
billion people who live under the shadow of DV infection. Other
well-known Flaviviruses include yellow fever virus, Japanese
encephalitis virus, West Nile virus [1,2], and Murray Valley
encephalitis virus [3]. The Dengue virus has four serotypes and is
transmitted by Aedes mosquitoes. Patients with DV infection show
various clinical symptoms that range from no significant illness or
mild fever to life-threatening Dengue hemorrhagic fever (DHF)
and Dengue shock syndrome (DSS) [4]. Currently, only supportive
treatments are available. Although considerable research has been
directed towards the development of a safe and effective DV
vaccine since the mid-20th century, there are no approved
commercial products available [5]. Therefore, to combat DV and
other related viral diseases, it is advisable to develop novel
strategies for discovering new antiviral agents. Recent progress in
the biology has brought with it many protein structures for virtual
screening (VS) as drug targets [6–9]. However, without a pre-
viously validated target site on the targeted protein as a reference
point, the number of lead candidates obtained from this type of
screening is very large. Cellular toxicity further complicates
biological activity assays as well. Therefore, the utilization of VS
is somewhat hindered by the processes that follow, namely, the
labor-intense, time-consuming verification process and the toxicity
assays required for processing large amounts of lead candidates.
Here, in an attempt to devise a less resource-demanding screening
process, we have focused on computational approaches that are
solely based on the structures of a designated region of the target
protein. Then, we performed VS on a set of medical compounds
because we recognized that using medical compounds could
potentially minimize cellular toxicity. To reduce the number of
lead candidates, we further refined the VS output by structural
clustering for the identification of novel structural characteristics.
Compounds with novel structures were then subjected to
a biological assay to validate their activities. In summary, we
sacrificed the diversity of leads in exchange for the efficiency of
screening.
The DV envelope (E) protein is 495 amino acids in length,
forms oligomers, and, along with the M protein, constitutes most
of the accessible virion surface that is covered by the envelope
membrane. The E protein is responsible for activating ‘‘membrane
fusion’’, the central molecular event during the entry of enveloped
RNA viruses into host cells. The Dengue virus enters a host cell
when the E protein binds to the virus receptor [10] on the host cell
surface and activates its conformational rearrangement, causing
the E protein in its dimeric pre-fusion form to transform into
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PLoS ONE | www.plosone.org 1 May 2007 | Issue 5 | e428a trimeric post-fusion structure. This essentially irreversible
conformational change induces the fusion between the viral
envelope membrane and the host cell membrane [11], allowing
entry to be completed. In short, the DV E protein mediates host
cell binding and is essential for infection via a conformation-
induced membrane fusion event between the host cell and the
virion. In addition, it is also the primary antigen that induces
protective immunity and the major antigen for virus neutralization
[10].
The crystal structures of the E protein of DV type 2 in both the
presence (pre-fusion) and absence (post-fusion) of a bound ligand
were deposited in the Protein Data Bank {PDB codes 1oke [5] and
1ok8 [11], respectively; Figure 1). The key difference between
these two structures is a local rearrangement of the ‘‘kl’’ b-hairpin
(residues 268–280) and the concomitant opening up of a hydro-
phobic pocket for ligand binding. For example, the detergent n-
octyl-b-D-glucoside (BOG) can occupy this pocket [11]. Mutations
that affect the pH threshold for membrane fusion have also been
mapped to this hydrophobic pocket [12,13]. Therefore, Modis et
al. proposed that this pocket was a hinge point in the fusion-
activating conformational change and suggested that it could be
a target site for the development of fusion inhibitors [5,11] that
could disrupt or even block the correct conformational changes
necessary for DV entry. This concept made the utilization of
structure-based VS to identify inhibitors of DV infection plausible.
Therefore, in this study, a well-developed docking tool, GEM-
DOCK [14–17], was utilized to perform VS on the Comprehensive
MedicinalChemistry(CMC)databaseforsubstancesthatcoulddock
in this hydrophobic pocket of E proteins [5]. These compounds were
then selectively tested, based on distinct structural characteristics, for
the inhibition of DV propagation. We have now successfully
identified two tetracycline derivatives [18,19] that displayed
significant inhibitory effects on the propagation of the DV type 2
PL046 strainincellcultures. According to the docked conformations
of these two active, and of two inactive tetracycline-derived
compounds, we have proposed a model for the inhibition of DV E
protein conformational change, which may provide a future
direction for lead compound optimization.
RESULTS
Virtual screening for inhibitors of the E protein
To assess the VS program, we first evaluated the docking accuracy
of GEMDOCK for the DV E protein by docking the detergent
ligand (BOG) into the binding site. The docked conformation of
BOG (Figure 2A) with the lowest scoring value was compared with
the crystal structure of BOG based on the root mean square
deviation (RMSD) of heavy atoms. The average RMSD of 10
independent runs was less than 1.20 A ˚. Molecular recognition of
the E protein was also investigated to determine the constraints of
the ligand and pharmacophore preferences during the VS. This
detergent-binding pocket, located at the juxtaposition of domains I
and II of the E protein, is hydrophobic in the pocket [5,11] and
hydrophilic on both sides of the protein surface.
GEMDOCK was then used to perform VS on the DV E
protein using a screening set from the CMC database that
contained 5,331 molecules between 200 and 800 Daltons. Since
the binding site of the DV E protein is hydrophobic, we set the
electrostatic constraint, based on the upper bound number of
charged atoms, to 0 and the hydrophilic constraint, based on the
upper bound fraction of polar atoms, to 0.3 (equation 4 in
Materials and Methods) to reduce the effects of GEMDOCK bias
toward charged polar compounds. The ligand preference served as
a hydrophilic filter and penalized compounds that had high
Figure 1. Pre-fusion (PDB code 1oke) and post-fusion (PDB code 1ok8) conformations of Dengue virus E protein and the ligand-binding pocket
for virtual screening. (A) Dengue virus E protein structures in pre-fusion (gray) and post-fusion (blue) states and the position of the binding regions
(black strand representing D9, k, l in pre-fusion state, colored strand representing the post-fusion state). (B) The conformation rearrangement of the
binding areas. Higher-order structures and domains I, II, and III are defined according to Modis et al. [11].
doi:10.1371/journal.pone.0000428.g001
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and pharmacophore preferences contributed to improvements in
the enrichment of VS [14,16], we used the scoring values of both
the empirical scoring function and pharmacophore-based scoring
function as ranking conditions to identify inhibitor candidates of
the DV E protein.
We selected the top-ranking 3% of compounds (,173
compounds, see Appendix S1 in supporting material) for further
analyses to enrich the hit rate after GEMDOCK screening. These
candidate compounds were then clustered using a hierarchical
cluster method based on both their two-dimensional compound
structures and protein-ligand interactions [20,21], similar to Jain’s
work [22]. Here, atomic environments [20,21] were used to
represent the two-dimensional compound structure for measure-
ments of compound similarities and the protein-ligand interactions
were used for the identification of docked positions and hot spots.
Based on structural similarities, docked positions, protein-ligand
interactions, and the limitations of commercial availability, two
groups of structures (Figure 3) distinguished themselves for use in
the in vivo plaque formation assay for their potential inhibitory
effects on DV propagation in cultured cells. One group consisted
of two tetracycline derivatives (tetracycline and rolitetracycline)
and the other group consisted of connected ring structures with
additional flexibility. To enrich possible hits, two more tetracycline
derivatives (doxycycline and oxytetracycline) under similar atomic
conditions were also included for the biological activity assay.
Docked conformations of these selected compounds are shown in
Figure 2B and the four tetracycline derivatives are indicated as
blue (rolitetracycline), green (doxycycline), orange (tetracycline),
and red (oxytetracycline). As shown in Figure 2A, BOG is docked
in the pocket and is situated centrally among Gly275, Lys128,
Leu277, and Gln52. All ten selected candidate compounds were
able to dock in the pocket at various locations (Figure 2B).
In vivo plaque formation assay
To assess whether those individual compounds obtained by
screening could indeed affect the propagation of Dengue virus
replication as predicted, different concentrations of the com-
pounds were added separately to cultures of BHK-21 cells,
followed immediately by the addition of the DV type 2 PL046
strain at a fixed number of plaque forming units (PFUs). If the
compounds bind to the E proteins as predicted, they may interfere
with the interactions between the E protein and the host surface
receptor, particularly with the E protein conformational change
that is necessary to activate viral entry. This inhibition would
reduce the frequency of DV infection in BHK-21 cells. Since every
successful infection leads to the formation of a plaque, the number
of plaques on the assay plate indicates the number of infection
events. As a fixed number of PFUs was originally added to the
culture, the reduction in the number of plaques reflected the
portion of the virion infection that was inhibited by the presence of
the particular compound. Therefore, using the number of PFUs
from the culture plates added only media (no compounds) as
100%, the relative percentage of the PFUs from the culture plates
with compounds was calculated. Of the 10 compounds, rolite-
tracycline and doxytetracycline (Figure 4) showed dramatic
inhibitory effects on DV propagation. In addition, another
compound, oxethazaine, also showed mild inhibition. There was
a 12% reduction (down to 88% from that of control) in the PFUs
when the concentration of oxethazaine in the culture was
increased from 200 mM to 500 mM. For 10 mM rolitetracycline,
there was almost no effect on DV plaque formation. But as the
concentration of rolitetracycline was increased, there were
significant inhibitory effects on DV propagation. Compared with
controls, there were only 20% of the PFUs remaining at 100 mM
and approximately 5% at 300 mM, yielding an estimated IC50
value of 67.1 mM (Figure 4). At 500 mM, there were less than 3%
Figure 2. Docked conformations of the candidate compounds in the BOG binding site according to GEMDOCK. The residues affecting the pH
threshold of fusion are indicated. (A) The crystal conformation is shown in the CPK model (i.e., oxygen in red, nitrogen in blue, and carbon in gray),
and the docked conformation of the BOG is shown in yellow. The formation of the hydrogen bonds is shown by a green dashed line. The RMSD of the
conformations is 1.20 A ˚, and both pre-fusion and post-fusion conformations form hydrogen bonds with Glu49 and Gln271. (B) The docked
conformations of the 10 selected compounds are shown. The four tetracycline derivatives are colored (doxycycline in green, rolitetracycline in blue,
tetracycline in orange, and oxytetracycline in red). The inhibitory compounds (doxycycline and rolitetracycline) are docked in the vicinity of residues
Thr48, Glu49, Ala50, Lys51, and Gln52.
doi:10.1371/journal.pone.0000428.g002
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PLoS ONE | www.plosone.org 3 May 2007 | Issue 5 | e428Figure 3. The ten compounds selected for competitive blocking assay of DV propagation. 1, rolitetracycline; 2, doxycycline; 3, tetracycline, 4,
oxytetracycline; 5, kanamycin; 6, proscillaridin; 7, astemizole; 8, ergosterol; 9, glipizide; 10, terfenadine.
doi:10.1371/journal.pone.0000428.g003
Figure 4. Effects of (A) doxycycline and (B) rolitetracycline on Dengue virus type 2 plaque formation using BHK-21 mammalian cells. The IC50
values of rolitetracycline and doxytetracycline are 67.1 mM and 55.6 mM, respectively. The x axis shows the percentage of the amount of plaque
formation compared with control. The y axis denotes the drug concentration.
doi:10.1371/journal.pone.0000428.g004
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retained at 10 mM and 14% were retained at 100 mM. When the
concentration of doxycycline reached 500 mM, there was only 1%
of the PFUs remaining, yielding an IC50 value of 55.6 mM
(Figure 4). Interestingly, neither tetracycline nor oxytetracycline
showed an effect on DV propagation at concentrations ranging
from 10 mM to 10 mM (data not shown), even though they share
the tetracyclic ring structure with both rolitetracycline and
doxycycline. Figure 5 shows the molecular structures and IC50
values of the tetracycline derivatives. These compounds had no
cellular toxicity effects within the range of concentrations tested as
judged from both cellular morphology and growth with one
possible exception. When the culture contained doxycycline at
a concentration of 500 mm or greater, the cell density appeared to
be reduced. We further tested the effects of those compounds by
the addition of 500 mm of individual compounds together with or
at intervals after the addition of DV to the cultured cells. The
results revealed that when 500 mM of either one of the active
compounds were added to the cell cultures together with a fixed
number of PFUs, the number of plaques formed was approx-
imately 3% or less compared with controls, whereas approxi-
mately 75% of the PFUs remained when the compound was
added 2 hours after the presence of viruses in the cell culture.
Therefore, the inhibitory effect is time-dependent. That is, if the
compounds are added after sufficient time was allowed for the
infection to proceed, the compounds lost potency.
Computational analysis of inhibitor-E protein
interactions
The docked conformations of the two tetracycline-derived
inhibitors were consistently different from those of the eight non-
inhibitory compounds according to the computation program used
(Figures 2B, 6, and 7). The inhibitors, doxytetracycline (green) and
rolitetracycline (blue) were docked on the outside of the binding
pocket and extended into the pocket while the non-inhibitory
compounds (CPK model) were docked inside the pocket
(Figure 2B). The inhibitors were docked between the D and I
segments of which the conformations significantly differed between
the pre-fusion and post-fusion forms (Figures 1B and 7). In fact, the
inhibitors were docked very close to or at the D9c space and their
tetracyclic structure was beneath D9c between D9c and Ic
Figure 5. Chemical Structures and IC50s for the tetracycline derivatives. Name, chemical name; IC50, the half maximal inhibitory concentration; NA,
not applicable.
doi:10.1371/journal.pone.0000428.g005
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hindrance by their structures per se but could also interact with the
polypeptide stretch of residues 48 to 52 via their functional groups
(Figure 6 A–B and 7 A–B). The residues in the stretch, formed by
Thr48, Glu49, Ala50, Lys51, and Gln52 and several others in the
vicinity, were shown to affect the pH-dependent membrane fusion
process [5,12,22–26]. The locations of these residues in the crystal
model are indicated in Figure 2. On the other hand, the two
inactive tetracycline compounds were docked further away from
the D9c space and their tetracyclic structures were localized above
D9o and D9c. Hence, they would not create steric hindrance during
the switch from D9o to D9c (Figure 7, C–D). Figure 6 shows the
hydrogen-bonding networks and orientations of the four tetracy-
cline derivatives with regard to the E protein in the pre-fusion
form. We also observed that the derivatives could be divided into
two groups by their docked locations. Those with inhibitory
effects, rolitetracycline (Figure 6A) and doxycycline (Figure 6B),
were docked in positions near residues 48–52 and formed
hydrogen-bonding networks with residues Thr48, Glu49, Ala50,
Lys51, and Gln52, as well as Gln271 and Gln200. Conversely, the
other two compounds, tetracycline (Figure 6C) and oxytetracycline
(Figure 6D), formed hydrogen bonds primarily with residues
Thr280, Phe279, Gln271, and Gln200. Tetracycline interacted
with the 48–52 stretch only at Thr48 while oxytetracycline
interacted with residues Thr48 and Ala50 and both appeared to
prefer Phe279 and Thr280. In addition, the inhibitors bound to
opposite sides of the surrounding wall (residues 48–52 vs. residues
200 and 271) of the binding pocket and extended their structures
centrally into the pocket, while the non-inhibitors bound entirely
to one side of the pocket (residues 200, 271, 279, 280, and 48)
(Figures 2B and 6). Furthermore, GEMDOCK yielded lower
binding energies for the two inhibitors than for the inactive
compounds. The energy minimization process performed by
SYBYL 6.9 also indicated that the predicted inhibitor complexes
had lower energies than the non-inhibitors. The energies of
rolitetracycline, doxytetracycline, tetracycline, and oxytetracycline
were 2395.2, 2398.7, 2356.8, and 2371.8 kcal/mol according
to SYBYL 6.9.
Figure 6. Docked conformations and hydrogen bonding of rolitetracycline (A), doxycycline (B), tetracycline (C), and oxytetracycline (D) to the
BOG binding site of the DV E protein. Atoms of the E protein are shown in yellow and compound ligands are shown in CPK model. The hydrogen
bonds are represented as green dashed lines. Not all residues are displayed for the sake of clarity. Thr48, Glu49, Ala50, Lys51, and Gln52 are in the D90
segment (Figure 1B), while Gln271 and Phe279 are in the ko and lo segments, respectively.
doi:10.1371/journal.pone.0000428.g006
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For the eradication of infections caused by enveloped viruses, the
identification of compounds that can block the function of viral
envelope proteins to prevent viral entry has been a long-standing
idea in the field. However, mass screening is usually considered too
costly and, for the more design-oriented approaches, VS with
limited information tends to yield too many candidates for
biological activity assays and is usually further complicated by
the cellular toxicity possessed by many of the candidates. Here, we
have devised a scheme in which VS focused on both the steric
hindrance and atomic environment between the compounds and
the targeted E protein to minimize the number of candidates. And,
to further reduce the number of candidates, instead of using the
whole E protein structure as the target for VS, we isolated the
small region around a chosen target site to serve as the target.
Although this approach may limit the diversity of the potential
leads due to the diminished choices of possible target sites for VS,
we believe that this methodology will, in fact, help to enhance the
chance of a successful hit because the program can screen many
more compounds with more thoroughness within the same time
frame. In this study, we chose the hydrophobic detergent-binding
pocket reported by Modis et al. as the target [5,11]. This putative
detergent-binding site is located in the E protein between domains
I and II, which are the key structural elements involved in the pH-
induced conformational rearrangement that is essential for DV
entry. Therefore, a suitable target for small-molecule inhibitors
would be the blockade of the conformational change of the E
protein and, subsequently, the inhibition of viral-host membrane
fusion, which would interrupt viral entry and block infection
[5,11]. Additionally, mutations in the DV E protein mapped to
this pocket indeed affect the pH threshold of fusion [5,12,22–26].
In short, based on the structural study of Modis et al. [5,11], we
developed a VS process and was successful in applying it to the
identification of lead compounds that inhibit DV propagation.
After computation, there were only ten non-toxic candidate
compounds that required validation by biological activity assays.
It is very interesting that in this study, even though tetracycline
and oxytetracycline share similar tetracyclic ring structures with
both rolitetracycline and doxycycline, they are not inhibitory
(Figure 5). Tetracycline derivatives are a group of broad-spectrum
antibiotics and were first discovered in the 1940s [19]. The
mechanism of action of tetracycline and its derivatives on bacteria
is via the inhibition of cellular protein synthesis by preventing the
attachment of aminoacyl tRNAs to the ribosomal acceptor (A) site
[18,19,27]. Those antibiotics consist of a linear, fused tetracyclic
core to which a variety of functional groups are attached [19].
Tetracycline, in fact, contains the minimal common structure of
the tetracycline-related molecules in this study. Therefore, this
common structure per se does not possess the inhibitory effect on
DV propagation. Instead, the substituted functional groups appear
to confer anti-Dengue virus activity.
On the other hand, it is also possible that the active compounds
affect the host cells instead of the virions. If this is the case, the
compounds might inactivate a host cellular component that is
essential for viral propagation. We believe that this scenario is
unlikely since there are no significant differences in cellular
morphology and growth, unless the function of such a cellular
component, when compromised, affects only the viruses. Nonethe-
less, to test this hypothesis, we performed an assay in which the
compounds were added to the cultures either together or 2 hours
after the presence of viruses in the cell cultures. If the compounds
were active against the viruses instead of the hosts, then adding
them together to the culture should effectively block viral infection
whereas the addition of the compounds 2 hours after the presence
of viruses would not have the same effect since the viruses would
have already proceeded through the entry event and infected the
host cells. As expected, when the compounds were added together
with the viruses, the PFUs were approximately 3% or less than
controls, whereas those added two hours later were approximately
75% of control levels. Therefore, the compounds were less potent
after the viruses had entered the host cells. Hence, these
compounds most likely act upon a virus target site and only affect
an event that occurs prior to the completion of viral entry.
Another possibility is that the compounds act on viral RNA at
locations where the RNA structures are similar to the tetracycline-
binding sites on the ribosomal RNAs or tRNAs of the bacteria.
This possibility requires that these compounds can penetrate the
virion structure to interact with the viral RNA to prevent viral
Figure 7. Docked conformations of the four tetracycline derivatives related to residues 48–52 in the BOG binding site in the pre-fusion (gray)
and post-fusion (blue) states. (A) rolitetracycline, (B) doxycycline, (C) tetracycline, and (D) oxytetracycline. Atoms within the compounds are
displayed using the CPK model (oxygen in red, nitrogen in blue, and carbon in gray). The side chains of certain residues that overlap with the
compounds are displayed. The segments D9o, ko, and lo are present in the pre-fusion conformation, while D9c, kc, and lc are present in the post-fusion
conformation.
doi:10.1371/journal.pone.0000428.g007
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inside the host cells when these same compounds are added two
hours later. We believe this scenario is also highly unlikely. First,
for the compounds to reach the viral RNAs in the virions, they
would have to overcome the physical obstacle consisting of viral
structural proteins. Second, if the viral RNAs are indeed the
targets, the compounds should be effective regardless of the time of
compound addition because they could still enter the host cells and
bind the viral RNAs to disrupt replication.
As for the possibility that the compounds affect viral proteins
other than the E protein, we believe that this scenario is also
unlikely since the E protein is the only protein required for viral
entry. However, we cannot rule out that the compounds may bind
at sites other than our predicted locations on the E protein. To
reveal the exact location of the compound-E protein interaction, it
may be necessary to devise an experiment, such as co-
crystallization of the protein and those compounds, in which the
compounds can be labeled and traced at an atomic level so their
exact docking locations can be identified relative to the binding
pocket.
Nonetheless, we have conducted computational modeling in an
attempt to provide a direction for future investigation. First, to
assess the results of the binding of tetracycline derivates to the DV
E protein, we compared the BOG binding sites of the DV E
protein to the tetracycline-binding site on the tetracycline
repressor, TetR. TetR regulates resistance to tetracycline in
gram-negative bacteria. The tetracycline-binding site of the TetR
protein has been defined and the structure determined by
crystallography [28]. We found that the TetR protein shares
similar characteristics with the E protein in the binding sites for the
tetracycline derivatives. First, there is an appropriate volume in the
binding sites. The volumes of the binding sites of various TetR
crystals range from 359 A ˚ 3 to 495 A ˚ 3 whereas the BOG binding
site on the E protein is 481 A ˚ 3, according to the tool program, Q-
SiteFinder [29] (the first column of Table S1). Therefore, there is
proper space for the tetracycline derivatives to fit into the BOG
binding site. Second, there are hydrophobic surfaces in the pockets
of both binding sites (Figure S1). Third, according to the results of
a cross-docking test performed for TetR and the tetracycline
derivatives (Table S1), the binding sites of the DV E protein and
TetR permit the binding of the tetracycline derivatives. In
addition, the hydrogen bonds formed between the tetracycline
derivatives and the DV E protein are similar to those between
TetR and the tetracycline-derived ligands (Table S2). Therefore,
tetracycline derivatives should reasonably bind the BOG pocket of
the DV E protein.
On the other hand, only two of the derivatives are inhibitory;
therefore, the atomic details of the functional groups and the
tetracyclic core must confer the inhibitory activity. Hence, we have
analyzed the docked conformations and hydrogen bonding of the
derivatives to assess the interaction between those compounds and
the E protein. There are distinct differences between the effective
and ineffective compounds (Figures 6, 7, and S2); the effective
compounds have their tetracyclic cores positioned inside the
pocket while their side chains form hydrogen bonds with the
residues located on the opposite sides of the wall around the pocket
and are capable of creating steric hindrance to the conformational
alteration of the E protein. In contrast, the ineffective compounds
form hydrogen bonds only with one side of the wall and their cores
lean away from the pocket.
Next,onanatomiclevel,thepredictedpositionsofthetetracycline
derivatives with the E protein are shown in Figures 6 and 7. The
fused tetracyclic rings of rolitetracycline and doxytetracycline bind
along the D9o strand and occupy the D9c space of the E protein. The
residues 48–52 are in the D segments. These compounds both
interact mainly with Thr48, Glu49, Ala50, Gln200, and Gln271
through hydrogen bonds. Such a hydrogen-bonding network
provides strong attraction forces to stabilize the binding of
rolitetracycline and doxytetracycline to the D9o strand and the kl
b-hairpin. In contrast, although these compounds have the same
tetracyclic core structures, neither tetracycline nor oxytetracycline is
inhibitory. Both compounds form hydrogen-bonding networks with
Thr48, Gln200, Gln271, Phe279, and Thr280 (Figure 6); therefore,
their tetracyclic rings are docked toward one side of the binding site
and contactthesurrounding hydrophobicresiduesviavanderWaals
interactions, which are very different from those of rolitetracycline
and doxytetracycline.
During the process of E protein-host membrane fusion, the E
protein structure is dramatically re-configured to allow the fusion
peptide to properly interact with the host membrane. This event is
marked by the rearrangement of the kl b-hairpin and the D9o
segment (Thr48, Glu49, Ala50, Lys51, and Gln52) in the BOG
binding site (Figures 1A and 6). The docked positions of the
inhibitors suggest that they occupy the D9c and kl b-hairpin spaces
in the post-fusion state and form a stable hydrogen-bonding
network (Figures 6A, 6B, 7A and 7B). Therefore, these compounds
block the rearrangement of the b-hairpin and D9o strand, and
thereby block the rearrangement of domains II and I of the E
protein during membrane fusion. Residues 48-52 are not only
important to inhibitor binding but may also directly affect
flavivirus membrane fusion. This hypothesis is consistent with
previous reports that Gln52 may affect the pH threshold of fusion
in flaviviruses [5].
Our study has presented a cost-effective and time-saving
screening process that is based on limited structural information.
We have successfully identified two novel tetracycline-derived
inhibitors of the propagation of flavivirus DV type 2 PL046, by the
computer-aided screening of the E protein structure followed by
the biological assay validation of the candidate compounds in a cell
culture system. These compounds may serve as the basis for the
development of new treatments against Dengue virus infection.
This procedure may be applied to other viral pathogens or for any
other mechanism that involves specific conformational alterations
for biological function. Our study also highlights the additional
characteristics of certain tetracycline derivatives as effective
inhibitors of DV propagation, which will allow further refinement
of our screening program and potential medical application.
MATERIALS AND METHODS
The VS method generally encompasses four phases that are based
on high-throughput molecular docking methods and the crystal
structures of the target proteins. These phases include target
protein preparation, compound database preparation, molecular
docking, and post-docking analysis [6]. The preparation phases
involve formatting the structural data from the target protein and
compounds into acceptable forms for the docking program. Then,
the method of molecular docking is employed to screen the
compound library for potential leads that can dock onto the target
protein, whereas post-docking analysis serves to enrich the hit rate.
Preparations of the target protein and screening set
We prepared the compound set from the CMC database in May
2004 based on two criteria: molecular weights ranging between
200 and 800 Daltons and excluding compounds with multiple
components. We eventually obtained a set of structures that
consisted of 5,331 compounds. To reduce the complexity and
running time of the computational program, we isolated the
Novel Flavivirus Inhibitors
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(Figure 1B) in the BOG-bound conformation {PDB code 1oke
[5]} and prepared it for the docking tools. The isolated area
included amino acids enclosed within a 10-A ˚ radius that centered
on the bound ligand. The coordinates of the protein atoms were
taken from the PDB for the screening process. GEMDOCK
docked each compound in the screening set against this binding
cavity and ranked each compound by the docked energy of the
docked conformation. Then, those candidates were subjected to
structural clustering [21]. According to the ranking, compound
structures and the interactions between compounds and residues
in the binding site were further selected for in vivo biological
activity assays to assess their inhibitory effect on Dengue virus
propagation in cell culture.
Docking method and scoring function
Our previous work [14–17] showed that the docking accuracy of
GEMDOCK was better than some well-known docking tools,
such as GOLD [30] and FlexX [31], on a diverse data set of 100
protein-ligand complexes suggested by Jones et al. [30]. The
accuracy of GEMDOCK was also better than GOLD, FlexX, and
DOCK on screening the ligand database from Bissantz et al. [32]
for TK [33] and the ER-antagonist receptor [16]. In this study,
GEMDOCK parameters for flexible docking included the initial
step sizes (s=0.8 and Y=0.2), family competition length (L=2),
population size (N=300), and recombination probability (pc=0.3).
For each ligand screened, GEMDOCK optimization was
terminated either when the convergence was below a certain
threshold value or when the iterations exceeded a maximal preset
value of 60. For the latter case, GEMDOCK produced 800
solutions in one generation and was terminated after it exhausted
48,000 solutions for each compound in the screening set.
The screening quality of the docking methods using energy-
based scoring functions alone is often influenced by the structure of
the ligand screened (e.g., the numbers of charged and polar
atoms). These methods are often biased toward charged polar
compounds due to the pair-atom potentials of the electrostatic and
hydrogen-bonding energies. In order to reduce this effect,
GEMDOCK can evolve the pharmacological preferences from
either a number of known active ligands or domain knowledge to
take advantage of the similarities of putative ligands to those that
are known to bind a protein’s active site, thereby guiding the
docking of the putative ligands [16]. Therefore, GEMDOCK is
capable of using either a purely empirical scoring function [15] or
a pharmacophore-based scoring function [16]. When GEM-
DOCK uses a pharmacophore-based scoring function, either
certain known active ligands (more than two) or domain
knowledge are required for the evolution of the pharmacological
consensus. The empirical binding energy (Ebind) is given as [15]:
EGEMDOCK{Binding~EinterzEintra ð1Þ
where Einter and Eintra are the intermolecular and intramolecular
energies, respectively [15]. The pharmacophore-based energy
function can be expressed as [16]:
EGEMDOCK{Pharma~EGEMDOCK{bindingzEpharmazEligpre ð2Þ
where EGEMDOCK-Bind is the empirical binding energy defined in
Equation (1), Epharma is the energy of the binding site pharmaco-
phores (hot spots), and Eligpre is the penalty value when a ligand
does not satisfy the ligand preferences [16]. Epharma and Eligpre are
especially useful in the selection of active compounds from
hundreds of thousands of non-active compounds by the exclusion
of ligands that violate the characteristics of known active ligands
(or domain knowledge). The pharmacophore-based interaction
energy (Epharma) between the ligand and the protein is calculated
with the assumption that the binding energies of all hot-spot atoms
can be represented by the following equation [16]:
Epharma~
X lig
i~1
X hs
j~1
CW Bij
  
Fr
Bij
ij
  
ð3Þ
where CW(Bij) is a pharmacological-weight function of a hot-spot
atom j with interaction type Bij, Fr
Bij
ij
  
is as defined previously
[15], lig is the number of heavy atoms in a screened ligand, and hs
is the number of hot-spot atoms in the protein. The ligand
preference (Eligpre) is the penalty value for the screened ligands that
violate the electrostatic or hydrophilic constraints. Eligpre is given as
[16]:
Eligpre~LPeleczLPhb: ð4Þ
where LPelec and LPhb are the penalties for the electrostatic (i.e., the
number of charged atoms in a screened ligand) and hydrophilic
(i.e., the fraction of polar atoms in a screened ligand) constraints,
respectively.
Plaque formation assay for the inhibitory effects of
compounds on DV2 propagation
A local DV type 2 strain, PL046, was used to infect mosquito C6/
36 cells for the production of DV type 2 virions. Mammalian BHK-
21 host cells were cultured at 37uC with 5% CO2 in MEM medium
(Gibco) supplemented with 0.22% sodium bicarbonate and 10%
fetal bovine serum (FBS) (Gibco). C6/36 cells were grown at 28uC
in MEM medium (Gibco) supplemented with 0.11% sodium
bicarbonate and 10% FBS [23]. BHK-21 cells were plated at
a density of 4610
5 cells per well in 6-well plates and incubated at
37uC with 5% CO2 for 48 hours. Different dilutions of the
compounds were added to the 6-well plates followed by 0.5 mL of
medium containing 200 PFUs of the DV type 2 PL046 strain per
well. The mixtures were mixed gently and then incubated at 37uC
with 5% CO2 for 1 hour. The supernatant in the culture was
aspirated prior to the addition of a 1:1 mixture of MEM
medium:2% methylcellulose. The culture was then incubated at
37uC with 5% CO2 for 7 days. The medium was aspirated prior to
fixation of the cells with 3.7% formaldehyde for 30 minutes. Then,
the fixing solution was removed and the cells were stained with 1%
crystal violet in 3.7% formaldehyde. Finally, the plates were
washed with 3.7% formaldehyde prior to scoring of plaques [34].
SUPPORTING INFORMATION
Table S1 GEMDOCK cross-docking results of docking seven
tetracycline-derivatives into five TetR protein structures and DV E
protein
Found at: doi:10.1371/journal.pone.0000428.s001 (0.02 MB
PDF)
Table S2 Comparisons of the hydrogen bonds of five
compounds between the dengue E protein and TetR protein
Found at: doi:10.1371/journal.pone.0000428.s002 (0.02 MB
PDF)
Figure S1 Docked conformations of the four tetracycline-
derivatives. The two active compounds are rolitetracycline (blue)
Novel Flavivirus Inhibitors
PLoS ONE | www.plosone.org 9 May 2007 | Issue 5 | e428and doxycycline (green). The two inactive compounds are
tetracycline (orange) and oxytetracycline (red). The inhibitory
compounds are docked in positions leaning on the residues of the
48–52 stretch, of which the conformations in prefusion and
postfusion states are very different. Residues affecting the pH
threshold of fusion are indicated by numbers.
Found at: doi:10.1371/journal.pone.0000428.s003 (0.07 MB
PDF)
Figure S2 The surfaces and the docked conformations of the
four tetracycline-derivatives on TetR protein and DV E protein
according to GEMDOCK. (A) TetR protein (PDB code 2TRT);
(B) DV E protein (PDB code 1OKE). The surfaces and sizes of the
binding sites of these two proteins are similar. In addition, docked
conformations of the four tetracycline-derivatives in these two
proteins are also similar.
Found at: doi:10.1371/journal.pone.0000428.s004 (0.09 MB
PDF)
Appendix S1 Appendix A: The top 173 compounds of
GEMDOCK by screening the CMC database.
Found at: doi:10.1371/journal.pone.0000428.s005 (0.18 MB
PDF)
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